ACLARION, INC(ACON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACON ACLARION, INC

Market Closed 04-02 16:00:00 EDT

3.57

+0.16

+4.69%

盘后3.57

+0.000.00%

19:59 EDT

High3.61	Low3.30	Vol56.24K
Open3.32	D1 Closing3.41	Amplitude9.09%
Mkt Cap8.15M	Tradable Cap8.15M	Total Shares2.28M
T/O198.36K	T/O Rate2.46%	Tradable Shares2.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACON","market":"US","secType":"STK","nameCN":"ACLARION, INC","latestPrice":3.57,"timestamp":1775160000000,"preClose":3.41,"halted":0,"volume":56236,"hourTrading":{"tag":"盘后","latestPrice":3.57,"preClose":3.57,"latestTime":"19:59 EDT","volume":968,"amount":3408.742,"timestamp":1775174375598,"change":0,"changeRate":0,"amplitude":0.019608},"delay":0,"changeRate":0.04692082111436941,"floatShares":2282300,"shares":2282371,"eps":-13.608688,"marketStatus":"Market Closed","change":0.16,"latestTime":"04-02 16:00:00 EDT","open":3.3228,"high":3.61,"low":3.3,"amount":198361.6533228,"amplitude":0.090909,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-13.608688,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":0,"listingDate":1650600000000,"exchange":"NASDAQ","adjPreClose":3.41,"preHourTrading":{"tag":"盘前","latestPrice":3.3011,"preClose":3.41,"latestTime":"09:15 EDT","volume":1003,"amount":3269.903369,"timestamp":1775135716723,"change":-0.1089,"changeRate":-0.031935,"amplitude":0.012053},"postHourTrading":{"tag":"盘后","latestPrice":3.57,"preClose":3.57,"latestTime":"19:59 EDT","volume":968,"amount":3408.742,"timestamp":1775174375598,"change":0,"changeRate":0,"amplitude":0.019608},"volumeRatio":1.7135136180654686},"requestUrl":"/m/hq/s/ACON","defaultTab":"news","newsList":[{"id":"2624729664","title":"Aclarion announces annual shareholder meeting, releases proxy statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624729664","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624729664?lang=en_us&edition=fundamental","pubTime":"2026-04-04 05:03","pubTimestamp":1775250211,"startTime":"0","endTime":"0","summary":"Aclarion scheduled 2026 annual meeting for June 4 in Broomfield, Colorado.Shareholders will vote to elect seven directors for terms running to 2027 annual meeting.Investors will also vote on amendment to 2022 Equity Incentive Plan, increasing share reserve to 500,000 from 42,974.Plan amendment would also lift annual per-participant award cap to 250,000 shares from 52 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL4pl8wb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622021442","title":"Aclarion Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2622021442","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622021442?lang=en_us&edition=fundamental","pubTime":"2026-03-25 17:42","pubTimestamp":1774431720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2026 05:42 ET (09:42 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621064345","title":"Echo Lake Capital urges Aclarion shareholders to oust director David Neal after 99% stock decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064345","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064345?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:01","pubTimestamp":1774353705,"startTime":"0","endTime":"0","summary":"Echo Lake Capital sent a letter to board member David K. Neal calling for his immediate resignation and alleging failures to act in shareholders’ best interests.The investor said the stock has declined 99% since the IPO and said Neal has received more than USD 240,000 in board compensation since 2021.The letter said Neal accepted a 20% pay increase in 2025 and currently owns two shares valued at USD 6.24.Echo Lake Capital also criticized recently adopted anti-takeover measures that it said make it harder to replace directors and limit how much stock a shareholder can buy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL6GBw68:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Echo Lake Capital urges Aclarion shareholders to oust director David Neal after 99% stock decline","news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620194225","title":"Aclarion board adopts one-year stockholder rights plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2620194225","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620194225?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:26","pubTimestamp":1773926762,"startTime":"0","endTime":"0","summary":"Aclarion’s board unanimously adopted a limited-duration stockholder rights plan that takes effect immediately and expires in one year.The board declared a dividend of one preferred stock purchase right for each common share and each Rights-Eligible Warrant outstanding at the close of business on March 30, 2026.Each right allows the holder to buy 1/1,000th of a share of Series D Junior Participating Preferred Stock for USD 14 per right, subject to adjustment.The rights become exercisable if an unapproved party acquires 10% or more beneficial ownership of common shares, with certain grandfathering provisions for existing holders at or above that level.The plan permits redemption at USD 0.001 per right and includes an exchange feature of one common share per right, and it is scheduled to expire on March 18, 2027 unless earlier redeemed, exchanged, or terminated in specified transactions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL9bhf6g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","ACON","BK4585","BK4588","IE00BN0W2W23.USD","IE00BGHQF748.EUR","SG9999014013.SGD","LU2210149790.SGD","LU0314104364.USD","IE00BKPKM429.USD","BK4112","NDAQ","LU2095319765.USD","BK4167","SG9999014005.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620198225","title":"Aclarion Inc - Rights Plan Expires March 18, 2027 Unless Earlier Redeemed, Exchanged, or Terminated","url":"https://stock-news.laohu8.com/highlight/detail?id=2620198225","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620198225?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:25","pubTimestamp":1773926740,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUA35TJ0K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACON","BK4167","ACONW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620162225","title":"Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2620162225","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620162225?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:25","pubTimestamp":1773926740,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUA35TJ0K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACONW","ACON","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620249539","title":"Aclarion’s CEO publishes shareholder letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2620249539","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620249539?lang=en_us&edition=fundamental","pubTime":"2026-03-19 18:11","pubTimestamp":1773915068,"startTime":"0","endTime":"0","summary":"Aclarion (ACON)published a shareholder letter from CEO Brent Ness providing an update on the company’s recent momentum and value-creating prioritie...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclarions-ceo-publishes-shareholder-letter-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclarions-ceo-publishes-shareholder-letter-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620469802","title":"Aclarion Inc. Announces Availability of CEO Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2620469802","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620469802?lang=en_us&edition=fundamental","pubTime":"2026-03-19 18:00","pubTimestamp":1773914429,"startTime":"0","endTime":"0","summary":"Aclarion said it published a CEO shareholder letter and made the full letter available on its website at .The letter, signed by CEO Brent Ness, provides an update on adoption of the Nociscan platform, clinical evidence development, and reimbursement initiatives in the UK and the US.It also references the CLARITY clinical trial, including an initial readout expected in Q4 2026.The letter notes a cash runway into 2028.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL3qDBlq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BN0W2W23.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","ACON","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","BK4588","SG9999014021.USD","LU2095319765.USD","BK4112","BK4167","LU2210150020.SGD","LU2210149790.SGD","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","SG9999014039.USD","IE00BGHQF748.EUR","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620245006","title":"Aclarion reports 114% year-over-year increase in Q4 2025 Nociscan scan volumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2620245006","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620245006?lang=en_us&edition=fundamental","pubTime":"2026-03-19 17:48","pubTimestamp":1773913712,"startTime":"0","endTime":"0","summary":"Nociscan scan volumes in Q4 2025 more than doubled, rising 114% year-over-year.In the U.K., three of the four largest private insurers provide reimbursement coverage for Nociscan, covering 5.2 million people out of 69 million.The company reported no outstanding debt and 2.88 million shares outstanding on a fully diluted basis.Aclarion said its cash runway extends into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief on March 19, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL7kT9B8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620267072","title":"Aclarion FY 2025 net loss was USD 7.23 million as sales and marketing expenses nearly doubled to USD 1.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620267072","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620267072?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:58","pubTimestamp":1773867531,"startTime":"0","endTime":"0","summary":"Aclarion published its annual report on Form 10-K for FY 2025. Revenue rose 65.6% to USD 75,730, driven primarily by growing Nociscan report volumes in the UK following local coverage decisions. Sales and marketing expense more than doubled to USD 1.9 million, reflecting higher post-clearance clinical services tied to the CLARITY Trial and increased product marketing consulting. Net loss was USD 7.23 million. The company said it had USD 12.04 million in cash and cash equivalents and restricted cash as of Dec. 31, 2025, and expects current cash to fund operations into the first quarter of 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via EDGAR, the Elec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL78c0w8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620428060","title":"Aclarion to Participate in 38th Annual ROTH Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2620428060","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620428060?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:02","pubTimestamp":1773741769,"startTime":"0","endTime":"0","summary":"Aclarion to Participate in 38th Annual ROTH Conference               Aclarion is scheduled to participate in the 38th Annual ROTH Conference on March 22-24, 2026, in Dana Point, California. The releas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLbQyk48:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","ACON","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2095319765.USD","LU0314104364.USD","BK4167","SG9999014021.USD","BK4588","LU2210149790.SGD","BK4585","LU2210150020.SGD","SG9999014013.SGD","NDAQ","SG9999014039.USD","SG9999014005.SGD","IE00BGHQF748.EUR","BK4112","IE00BN0W2W23.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618138346","title":"Aclarion CEO Brent Ness to Attend LSI USA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618138346","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618138346?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:01","pubTimestamp":1773309711,"startTime":"0","endTime":"0","summary":"Aclarion said CEO Brent Ness will attend LSI USA 2026 on March 16-20, 2026, in Dana Point, California.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL2pvZB3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4588","BK4585","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014005.SGD","SG9999014021.USD","ACON","LU2095319765.USD","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","NDAQ","BK4167","BK4112","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609756376","title":"Aclarion Inc - Has Cash Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2609756376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609756376?lang=en_us&edition=fundamental","pubTime":"2026-02-05 19:06","pubTimestamp":1770289574,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nFWN3Z10SE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","ACON","ACONW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608882792","title":"Aclarion schließt Vereinbarung mit Source Healthcare zur Nutzung von Nociscan","url":"https://stock-news.laohu8.com/highlight/detail?id=2608882792","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608882792?lang=en_us&edition=fundamental","pubTime":"2026-02-03 19:00","pubTimestamp":1770116457,"startTime":"0","endTime":"0","summary":"Aclarion Inc. hat eine Vereinbarung mit Source Healthcare, einer orthopdischen und regenerativen Klinik in Los Angeles, geschlossen. Ziel ist die Erweiterung der Verfügbarkeit der Nociscan-Lsung zur Identifikation von chronischen Rückenschmerzen. Die Zusammenarbeit soll die Generierung von Real-World-Evidenz unterstützen und die Nutzung von Nociscan im Vergleich zur ansthetischen Diskographie untersuchen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via GlobeNewswire  on February 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL61Hy2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4112","BK4167","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014021.USD","SG9999014005.SGD","NDAQ","BK4585","SG9999014039.USD","IE00B64PRP62.GBP","SG9999014013.SGD","LU2210149790.SGD","LU0314104364.USD","ACON","BK4588","LU2095319765.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603635775","title":"Aclarion Raises $10.4 Million, Sharpens Focus On Nociscan Rollout","url":"https://stock-news.laohu8.com/highlight/detail?id=2603635775","media":"Benzinga_recent_news","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603635775?lang=en_us&edition=fundamental","pubTime":"2026-01-13 23:51","pubTimestamp":1768319460,"startTime":"0","endTime":"0","summary":"Aclarion, Inc. (NASDAQ: ACON) closed a $10.4 million financing at $5.18/share, boosting balance sheet & extending cash runway to 2028.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/13/Ipo-Initial-Public-Offering--Business-Ma.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/13/Ipo-Initial-Public-Offering--Business-Ma.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49879642/aclarion-raises-10-4-million-sharpens-focus-on-nociscan-rollout","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49879642/aclarion-raises-10-4-million-sharpens-focus-on-nociscan-rollout","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603687704","title":"BRIEF-Aclarion Inc - Extends Cash Runway Into 2028 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2603687704","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603687704?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:07","pubTimestamp":1768313279,"startTime":"0","endTime":"0","summary":"BRIEF-Aclarion Inc - Extends Cash Runway Into 2028 - SEC FilingJan 13 (Reuters) - Aclarion Inc ACON.O:ACLARION INC - EXTENDS CASH RUNWAY INTO 2028 - SEC FILINGFurther company coverage: ACON.O ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE10N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601395854","title":"Aclarion Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2601395854","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601395854?lang=en_us&edition=fundamental","pubTime":"2026-01-08 23:00","pubTimestamp":1767884434,"startTime":"0","endTime":"0","summary":"09:59 EST Aclarion (ACON) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclarion-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclarion-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601622673","title":"Aclarion's AI Back Pain Tech Sees 114% Surge In Demand, Stock Soars","url":"https://stock-news.laohu8.com/highlight/detail?id=2601622673","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601622673?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:29","pubTimestamp":1767878940,"startTime":"0","endTime":"0","summary":"Aclarion Inc. (NASDAQ: ACON) provided a corporate update on Thursday, reporting strong commercial momentum.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/08/Muscular-Man-Suffering-From-Back-And-Nec.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/08/Muscular-Man-Suffering-From-Back-And-Nec.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/01/49781264/aclarions-ai-back-pain-tech-sees-114-surge-in-demand-stock-soars","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/01/49781264/aclarions-ai-back-pain-tech-sees-114-surge-in-demand-stock-soars","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601548363","title":"Aclarion Launches CLARITY Trial to Advance Nociscan for Chronic Low Back Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2601548363","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601548363?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:00","pubTimestamp":1767870048,"startTime":"0","endTime":"0","summary":"Aclarion Inc. has announced the launch of the CLARITY trial in 2025, with seven activated sites. The company aims to enroll approximately 25% of patients in the trial by the end of the second quarter of 2026, with the first internal readout on interim data anticipated in the third quarter of 2026. The CLARITY trial is part of Aclarion’s strategy to advance clinical validation for its Nociscan platform, a cloud-based solution utilizing MR spectroscopy and augmented intelligence to identify the location of chronic low back pain. Results from this trial have not yet been presented; interim data is expected in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL5gwfj1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU0314104364.USD","IE00BGHQF748.EUR","LU2095319765.USD","LU2210149790.SGD","SG9999014013.SGD","SG9999014021.USD","LU2210150020.SGD","BK4112","SG9999014039.USD","BK4588","ACON","NDAQ","BK4585","IE00B3QW5Z07.USD","BK4167","IE00BKPKM429.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601635553","title":"Aclarion Inc - Aims to Enroll 25% in Clarity Trial by Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601635553","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601635553?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:00","pubTimestamp":1767870001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA5QWL3R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","ACONW","ACON"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclarion.com","stockEarnings":[{"period":"1week","weight":0.0884},{"period":"1month","weight":0.3321},{"period":"3month","weight":-0.2831},{"period":"6month","weight":-0.5143},{"period":"1year","weight":-0.7169},{"period":"ytd","weight":-0.2239}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.316115},{"month":2,"riseRate":0.25,"avgChangeRate":-0.352706},{"month":3,"riseRate":0.25,"avgChangeRate":-0.242097},{"month":4,"riseRate":0.25,"avgChangeRate":-0.107915},{"month":5,"riseRate":0.5,"avgChangeRate":0.044825},{"month":6,"riseRate":0.25,"avgChangeRate":-0.115199},{"month":7,"riseRate":0.5,"avgChangeRate":-0.021585},{"month":8,"riseRate":0.5,"avgChangeRate":-0.066272},{"month":9,"riseRate":0.25,"avgChangeRate":-0.18466},{"month":10,"riseRate":1,"avgChangeRate":0.110748},{"month":11,"riseRate":0,"avgChangeRate":-0.1724},{"month":12,"riseRate":0,"avgChangeRate":-0.242895}],"exchange":"NASDAQ","name":"ACLARION, INC","nameEN":"ACLARION, INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ACLARION, INC(ACON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ACLARION, INC(ACON) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ACLARION, INC,ACON,ACLARION, INC股票,ACLARION, INC股票老虎,ACLARION, INC股票老虎国际,ACLARION, INC行情,ACLARION, INC股票行情,ACLARION, INC股价,ACLARION, INC股市,ACLARION, INC股票价格,ACLARION, INC股票交易,ACLARION, INC股票购买,ACLARION, INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ACLARION, INC(ACON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ACLARION, INC(ACON) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction